JANX
HealthcareJanux Therapeutics, Inc. · Biotechnology · $890M
What is Janux Therapeutics, Inc.?
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies. Headquartered in La Jolla, California, it was incorporated in 2017.
Janux develops cancer treatments using its proprietary TRACTr and TRACIr platform technologies, which are designed to selectively activate immune cells within the tumor environment. The company generates no product revenue yet, funding operations through capital raises while advancing candidates targeting prostate, lung, and other cancers through preclinical and early clinical stages.
Janux Therapeutics was incorporated in 2017 and is based in La Jolla, California.
- Tumor Activated T Cell Engager (TRACTr) platform
- Tumor Activated Immunomodulator (TRACIr) platform
- PSMA-targeted TRACTr candidate for prostate cancer
- EGFR-targeted TRACTr candidate for multiple cancer types
Is JANX a Good Stock to Buy?
UQS Score rates JANX as Poor overall, reflecting the early-stage nature of the business.
The Risk pillar stands out as the relative bright spot, suggesting the company carries a manageable near-term financial risk profile compared to many peers at a similar development stage.
Quality, Moat, and Growth pillars all register as Weak, consistent with a pre-revenue biotech that has yet to establish durable competitive advantages or a commercial track record. Valuation is rated Elevated.
See the full pillar breakdown and detailed financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does JANX pay dividends?
No — Janux Therapeutics, Inc. does not currently pay a dividend.
JANX does not pay a dividend. As a pre-revenue biopharmaceutical company, Janux directs all available capital toward research, clinical development, and platform advancement rather than shareholder distributions.
When does JANX report earnings?
Janux Therapeutics reports financial results on a quarterly cadence, typical for US-listed equities.
As a pre-revenue company, quarterly reports focus primarily on cash runway, pipeline milestones, and operating expenses rather than sales or profit trends. Clinical and regulatory updates tend to be the most market-moving disclosures.
For the most recent quarter's results, visit Janux Therapeutics' investor relations page directly.
JANX Price History
-38.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Janux Therapeutics, Inc.?
Based on Janux Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Janux Therapeutics do?
Janux Therapeutics develops cancer immunotherapies using its proprietary TRACTr and TRACIr platforms. These technologies are designed to activate T cells selectively within tumors, aiming to improve efficacy while reducing side effects common with traditional cancer treatments.
Does JANX pay dividends?
No, JANX does not pay a dividend. The company is pre-revenue and reinvests all capital into research and clinical development. Income-focused investors should be aware that no distributions are expected in the near term.
When does JANX report earnings?
Janux Therapeutics follows a standard quarterly reporting schedule. Because the company is pre-revenue, reports center on pipeline progress and cash position. Check the company's investor relations page for the latest scheduled dates.
Is JANX a good stock to buy?
UQS Score rates JANX as Poor overall. The Quality, Moat, and Growth pillars are all Weak, and Valuation is Elevated. The Risk pillar is the relative strength. Investors should weigh these factors carefully against their own risk tolerance.
Is JANX overvalued?
The UQS Valuation pillar for JANX is rated Elevated, suggesting the market is pricing in significant future success relative to the company's current development stage. This is common for early-stage biotechs but adds risk if clinical milestones are delayed.
What is JANX's market cap bracket?
JANX is classified as a small-cap stock. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk than large- or mega-cap peers.
Is JANX a long-term quality investment?
From a quality-indicator standpoint, JANX scores Poor on the UQS composite. Long-term quality investing typically favors companies with established moats and consistent financial performance — characteristics Janux has yet to demonstrate as a clinical-stage company.
What sector does JANX belong to?
JANX operates in the Healthcare sector, specifically within biopharmaceuticals. It focuses on oncology, developing platform-based immunotherapies rather than small-molecule drugs, which differentiates its scientific approach within the broader sector.
Unlock Full JANX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for JANX
- ✓Access detailed financial metrics and trend data
- ✓Compare JANX against sector peers on quality and risk
- ✓Get the full analyst-style profile in one place
Pro Analysis
JANX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 15.9 | 0.4 | 14.0 | 5.7 | 74.5 | 0.0 | — |
JANX — Pillar Breakdown
Quality
— 0.4/100 (25%)Janux Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 5.7/100 (20%)Janux Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.1/100 (15%)Janux Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Janux Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Janux Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for JANX.
Score Composition
Financial Data
More Stock Analysis
How is the JANX UQS Score Calculated?
The UQS (Unified Quality Score) for Janux Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Janux Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Janux Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.